Taiko Pharmaceutical Co (TSE:4574) EBIT : 円-2,884 Mil (TTM As of Mar. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Taiko Pharmaceutical Co EBIT?

Taiko Pharmaceutical Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was 円431 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was 円-2,884 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Taiko Pharmaceutical Co's annualized ROC % for the quarter that ended in Mar. 2024 was 14.04%. Taiko Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 30.67%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Taiko Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -17.51%.

Taiko Pharmaceutical Co EBIT Historical Data

The historical data trend for Taiko Pharmaceutical Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taiko Pharmaceutical Co EBIT Chart

Taiko Pharmaceutical Co Annual Data

Trend

Mar13

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Dec21

Dec22

EBIT

Get a 7-Day Free Trial

1,857.05

2,029.93

3,504.72

-8,881.00

-4,859.00

Taiko Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															-240.00	-248.00	-43.00	-3,024.00	431.00

Competitive Comparison of Taiko Pharmaceutical Co's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Taiko Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Taiko Pharmaceutical Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Taiko Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Taiko Pharmaceutical Co's EV-to-EBIT falls into.

Taiko Pharmaceutical Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-2,884 Mil.

Taiko Pharmaceutical Co (TSE:4574) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Taiko Pharmaceutical Co's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	860 * ( 1 - -9.79% )	/	( (6579	+	6873)	/ 2 )
=	944.194	/	6726
=	14.04 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	13220	-	1157	-	( 5484	-	max(0, 3046	-	9109	+	5484	))
=	6579

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	12997	-	886	-	( 5238	-	max(0, 2500	-	8764	+	5238	))
=	6873

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Taiko Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	1724	/	( ( (3581 + max(1812, 0))	+	(3548 + max(2302, 0)) )	/	2 )
=	1724	/	( ( 5393	+	5850 )	/	2 )
=	1724	/	5621.5
=	30.67 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1985	+	1373	+	267)	-	(1157	+	0	+	656)
=	1812

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1935	+	1472	+	119)	-	(886	+	0	+	338)
=	2302

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Taiko Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-2884	/	16471.153
	=	-17.51 %

Taiko Pharmaceutical Co EBIT Related Terms

Thank you for viewing the detailed overview of Taiko Pharmaceutical Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Taiko Pharmaceutical Co (TSE:4574) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taiko Pharmaceutical Co Ltd (TSE:4574) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 34 Third Street, No. 14, Uchihon Suita, Osaka, JPN, 564-0032

Website

http://www.seirogan.co.jp

Taiko Pharmaceutical Co Ltd operates in three segments, namely Pharmaceutical, Infection Control, and Others. The majority of its revenue comes from Infection Control, which is into manufacturing and sales of sanitation control products, including Cleverin, Cleverin LED, and Cleverin Generator LISPASS. The pharmaceutical segment is into the manufacturing and sales of OTC medicines and designated quasi-drugs. Other business includes manufacturing and sales of wood vinegar-based products.

Taiko Pharmaceutical Co (TSE:4574) Headlines

No Headlines